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Background
Kaposi’s sarcoma(KS) is the most common AIDS related
malignancy in Malawi. National guidelines recommend
chemotherapy with vincristine, along with antiretroviral
treatment (ART). Effectiveness of vincristine monother-
apy is limited, is considered palliative and interrupted
supply contributes to poor outcomes of KS patients.
Lighthouse, a major provider of HIV related services,
started 38 patients on ART due to KS in quarter 1, 2010
and overall, 1195 patients ever started ART due to KS.
Purpose of the study
To improve KS patient care,we introduced a combined
treatment with vincristine(V), bleomycin(B) and doxoru-
bicin(D), supplied by the central hospital pharmacy,
developed standardized monitoring forms and trained
providers in KS management.
Methods
Clinicians stage KS patients’ tumor severity (T0-good
risk, T1-poor risk)and presence of systemic illness (SO-
good risk, S1-poor risk) using a standardized clinical
assessment form and record information about prior
chemotherapy and ART. The form guides clinical deci-
sions on regimen selection and accurate dosage. From
initiation of chemotherapy, clinical officers examine
patients and record lesion size at each subsequent visit.
Nurses administer the treatment. Doses vary depending
on clinical findings and body surface area. A specialist
physician reviews patients with side effects.
Results
Between 2nd June and 30th July 2010, 48 adult KS
patients (35men) all of them with a prior history of vin-
cristine monotherapy, started combined chemotherapy:
30(62%) received BV and 18(38%) received DBV. No
patient developed side effects so far, and all of them are
alive. Forty-six(96%) patients were already on ART at
the time of chemotherapy initiation. 44 on d4T/3TC/
NVP, one on d4T/3TC/EFV and one on AZT/3TC/
TDF/LOP/r. All patients had severe KS manifestations
(T1) with skin edema, pulmonary or gastrointestinal
involvement, but only 5(10%) had systemic illnesses
(S1), such as pneumonia, pulmonary TB or malaria
requiring stabilization and co medication prior to che-
motherapy. Bleomycin and vincristine were not available
for 1 week.
Conclusions
Combination chemotherapy for KS patients appears to
be feasible in a resource poor public health clinic setting
and may be helpful to improve outcomes of patients
non responsive to standard vincristine monotherapy and
ART. Ensuring a continuous supply of all chemotherapy
agents is a priority.
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